Table 1.
Demographic, laboratory and clinical characteristics
| Control EN Group 1 n.15 |
GLN-enriched EN Group 2 n.15 |
p value | |
|---|---|---|---|
| Age (y) | 53.5±11.4 | 54.0±11.7 | 0.57 |
| Weight (kg) | 76±16.4 | 74.53±16.9 | 0.48 |
| Height (cm) | 165±9.2 | 165±7.5 | 0.22 |
| BMI (kg/cm2) | 28.7±8.1 | 29.1±8.9 | 0.19 |
| Sex (M/F) | 8/7 | 10/5 | 0,17 |
| Albumin (g/dl) | 2.5±0.9 | 2.8±0.6 | 0.82 |
| Proteins (g/dl) | 5.3±0,9 | 6.2±0.8 | 0.91 |
| Plasmatic urea level (mmol/litre) | 41±9.2 | 45±8.1 | 0.46 |
| GCS score | 11±2 | 12±3 | 0.40 |
| ISS score | 27.5±10.1 | 40.9±19.8 | 0.09 |
| SAPS score | 45.4±12.1 | 45.8±9.8 | 0.9 |
| APACHES II score | 23.6±3.6 | 21.4±6.3 | 0.76 |
| ICU length of stay (days) | 25±5 | 20±7 | 0.39 |
| ICU mortality, n (%) | 6 (40) | 5 (33.3) | 0.4 |
| MV time (d) | 9.26±1.3 | 9±1.4 | 0.31 |